Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 11.66 USD Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Avadel Pharmaceuticals PLC?
Write Note

Avadel Pharmaceuticals PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Avadel Pharmaceuticals PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Total Current Liabilities
$42.8m
CAGR 3-Years
34%
CAGR 5-Years
6%
CAGR 10-Years
-1%
Perrigo Company PLC
NYSE:PRGO
Total Current Liabilities
$1.5B
CAGR 3-Years
-10%
CAGR 5-Years
2%
CAGR 10-Years
4%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Total Current Liabilities
$1B
CAGR 3-Years
12%
CAGR 5-Years
21%
CAGR 10-Years
16%
G
GH Research PLC
NASDAQ:GHRS
Total Current Liabilities
$6.7m
CAGR 3-Years
222%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Total Current Liabilities
€37.9m
CAGR 3-Years
32%
CAGR 5-Years
18%
CAGR 10-Years
12%
Ovoca Bio PLC
LSE:OVB
Total Current Liabilities
€452k
CAGR 3-Years
-29%
CAGR 5-Years
32%
CAGR 10-Years
-16%
No Stocks Found

Avadel Pharmaceuticals PLC
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

AVDL Intrinsic Value
17.53 USD
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Avadel Pharmaceuticals PLC's Total Current Liabilities?
Total Current Liabilities
42.8m USD

Based on the financial report for Sep 30, 2024, Avadel Pharmaceuticals PLC's Total Current Liabilities amounts to 42.8m USD.

What is Avadel Pharmaceuticals PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-1%

Over the last year, the Total Current Liabilities growth was -21%. The average annual Total Current Liabilities growth rates for Avadel Pharmaceuticals PLC have been 34% over the past three years , 6% over the past five years , and -1% over the past ten years .

Back to Top